Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted

Oncology was the only space with significant FDA regulatory activity in the past week, headlined by two approvals.

FDA cleared one novel agent, Pfizer Inc.'s antibody-drug conjugate Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia, and approved broader use of AstraZeneca PLC's ovarian cancer therapy Lynparza (olaparib). The agency also received applications for new indications for Seattle Genetics Inc.'s antibody drug conjugate Adcetris (brentuximab vedotin), Exelixis Inc